US EditionPublished • loading... • Updated
Continued Zenocutuzumab Treatment Beyond Progression Shows Benefit in Patients with NRG1+ Pancreatic Cancer and Cholangiocarcinoma: New Results from the eNRGy Trial Presented at ASCO GI
Post hoc eNRGy trial analysis shows 65% clinical benefit rate and median therapy duration of 11 months for zenocutuzumab beyond progression in NRG1+ pancreatic and biliary cancers.
- On Jan. 9, 2026 Partner Therapeutics, Inc. announced a post hoc eNRGy trial analysis of zenocutuzumab in advanced NRG1+ PDAC and CCA patients continuing treatment beyond progression.
- NRG1 fusions act as oncogenic chimeric ligands, distinct drivers, while zenocutuzumab-zbco blocks HER2/HER3 dimerization and NRG1–HER3 interactions, targeting this biology.
- In the post hoc subset, 17 patients showed an overall response rate of 35% and clinical benefit rate of 65%, with median total therapy duration of 11 months and median 2 months post-progression.
- Partner Therapeutics reported fatal adverse reactions in 3% of patients, ILD/pneumonitis in 1.1%, and permanent discontinuation due to adverse reactions in 3%.
- PanCAN and guidelines recommend comprehensive molecular testing, notably tissue-based RNA next-generation sequencing, while continued approval requires confirmatory trials; Alison M. Schram, MD, said, `These findings highlight an important therapeutic opportunity for patients with NRG1 fusion-positive pancreatic and biliary cancers, which are often difficult to treat.
Insights by Ground AI
14 Articles
14 Articles
The Courier-Tribune+13 Reposted by 13 other sources
Continued Zenocutuzumab Treatment Beyond Progression Shows Benefit in Patients with NRG1+ Pancreatic Cancer and Cholangiocarcinoma: New Results from the eNRGy Trial Presented at ASCO GI
LEXINGTON, Mass., Jan. 9, 2026 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, announced new data from a post hoc analysis of the eNRGy trial (NCT02912949), evaluating zenocutuzumab in patients with advanced neuregulin 1 fusion-positive (NRG1+)…
Coverage Details
Total News Sources14
Leaning Left1Leaning Right3Center4Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
13%
C 50%
R 37%
Factuality
To view factuality data please Upgrade to Premium
